Effect of Tactile/Kinaesthetic Massage Therapy on DXA Parameter of Preterm Infants

Effect of Tactile/Kinaesthetic Massage Therapy on Growth Parameters and Body Composition of Preterm Infants

The effect of Tactile/Kinaesthetic massage therapy on weight gain and different components of growth, as assessed by anthropometric measurements and DXA scan, and correlate these components with serum IGF-1, leptin and adiponectin in preterm infants.

Study Overview

• Status: Completed
• Conditions: Body Composition; Preterm Infant; Dual X-ray Absorptiometry (DXA) Scan
• Intervention / Treatment: Procedure: Massage Therapy

Detailed Description

Prospective open label randomized, single-blind, controlled trial was done in the NICU at Mansoura University Children's Hospital.

Stable preterm infants in the NICU awaiting for sustained pattern of weight gain were included in the study.

Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field. Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation.

During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying). Vital signs are measured 15 minutes before, 15 minutes during and 15 minutes after the massage procedure. If signs of physiologic distress developed (heart rate greater than 200 bpm), massage was discontinued for 15 seconds, or until a return to baseline levels.

The study was discontinued if five periods of observed behavioural or physiological stress occurred.

Body composition assessment using DXA scan was performed for total body All infants were studied on one occasion by the end of 5 days massage therapy. DXA scan was performed without sedation but a pacifier with non-metallic parts was used as needed. The scanning procedure was interrupted if movement artefacts is noted. In addition, analyses of different body regions were also performed. Regional analyses typically involved the head, each of the four extremities, and the trunk.

Blood samples were collected using standard technique at baseline and after 5 days for measurement of IGF-1, leptin and adiponectin levels using Enzyme-linked Immunosorbent Assay [ELISA kit supplied by Elabscience Biotechnology (No.1 Shizishan Street, Wuhan, Hubei, China) catalog No: E-EL-H0086].

Randomization Infants were assigned randomly, by a designated neonatologist, to treatment groups using internet based random table technique with cards in opaque sealed envelopes that were kept in the neonatal care unit. A written informed consent was obtained from the parents of each infant upon enrolment in the study. Procedures of MT, DXA scan, and laboratory analysis were performed by a designated personnel throughout the study to ensure consistency. Performers of DXA scan and laboratory measures were blinded to groups of intervention.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Egypt
  • Mansourah, Egypt
  • El Dakahlya
    • Mansourah, El Dakahlya, Egypt, 35111
      • Mansoura University Children Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 months to 8 months (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Medically stable premature infants with gestational age at 28 to 37 weeks' admitted to the "grower" (step-down) nursery. Stability is defined as lack of need for supplemental oxygen, apneas and bradycardias, systemic antimicrobial therapy for infection, or a central line. On at least 100 ml/kg/d of feed (oral or tube feed) preterm formula. informed consent will be obtained from parents before enrollment in the study.

Exclusion Criteria:

• History of necrotizing enterocolitis, receipt of postnatal steroids, active infection, congenital malformations, chromosomal abnormality, intracranial hemorrhage more than (>) grade 2, inborn errors of metabolism, meningitis or encephalopathy, need for surgery.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control; Infants in this group will receive ordinary supportive care and will not receive Massage Therapy
Active Comparator: Massage group; Infants in this group will receive Massage Therapy Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006). During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying).	Procedure: Massage Therapy; Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Growth parameter (Weight)	Daily weight gain in grams and cumulative weight gain after 5 days of intervention	5 days
Growth parameter (Length)	Daily length gain in cm and cumulative length gain after 5 days of intervention	5 days
Growth parameter (Head circumference)	Daily head circumference gain in cm and cumulative head circumference gain after 5 days of intervention	5 days
Growth parameter (Mid-arm circumference)	Daily mid-arm circumference gain in cm and cumulative mid-arm circumference gain after 5 days of intervention	5 days
Growth parameter (Ponderal Index)	Daily changes in Ponderal Index and cumulative changes in Ponderal Index after 5 days of intervention	5 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dual X-ray absorptiometry scan (DXA scan)	DXA scan will be performed prior to and 5 days after massage therapy to measure bone mineral density at different levels in the body	5 days
Insulin-like Growth Factor 1 (IGF-1)	Serum level of IGF-1 will be measured at baseline and 5 days after massage therapy	5 days
Serum Leptin	Serum level of Leptin will be measured at baseline and 5 days after massage therapy	5 days
Serum adiponectin	Serum level of adiponectin will be measured at baseline and 5 days after massage therapy	5 days

Collaborators and Investigators

• Sponsor: Mansoura University Children Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2014
• Primary Completion (Actual): December 1, 2018
• Study Completion (Actual): December 1, 2018

Study Registration Dates

• First Submitted: January 21, 2018
• First Submitted That Met QC Criteria: January 21, 2018
• First Posted (Actual): January 26, 2018

Study Record Updates

• Last Update Posted (Actual): June 8, 2022
• Last Update Submitted That Met QC Criteria: June 7, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pregnancy Complications; Obstetric Labor Complications; Obstetric Labor, Premature; Premature Birth
• Other Study ID Numbers: NICU MUCH 2017

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No